Table 2.
Performance of the MSC test in the CTind and CT+ groups in terms of sensitivity, specificity, positive predictive value and negative predictive value.
| TOTAL exams |
MSC− |
MSC+ |
Sens | Spec | PPV | NPV | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| N | % of total exams | N | % of total exams | N | % of total exams | |||||
| CTind | 1403 | 894 | 509 | |||||||
| LC within 1 year | 9 | 0.6% | 2 | 0.2% | 7 | 1.4% | 78% | 64% | 1% | 100% |
| LC within 2 years | 48 | 3.4% | 20 | 2.2% | 28 | 5.5% | 58% | 65% | 6% | 98% |
| Total LC | 136 | 9.7% | 78 | 8.7% | 58 | 11.4% | 43% | 64% | 11% | 91% |
| CT+ | 584 | 296 | 288 | |||||||
| LC within 1 year | 90 | 15.4% | 24 | 8.1% | 66 | 22.9% | 73% | 55% | 23% | 92% |
| LC within 2 years | 120 | 20.5% | 34 | 11.5% | 86 | 29.9% | 72% | 56% | 30% | 88% |
| Total LC | 156 | 26.7% | 50 | 16.9% | 106 | 36.8% | 68% | 57% | 37% | 83% |
CTind, computed tomography indeterminate; CT+, computed tomography positive; LC, lung cancer; MSC, 24-microRNA signature classifier; NPV, negative predictive value; PPV, positive predictive value; Sens, sensitivity; Spec, specificity.